PTEN and cancer: Considering that PTEN is one of the most frequently mutated genes in cancer [3,4], with 40–80% of most human tumors acquiring somatic PTEN mutation, deletion, and/or loss of heterozygosity [74,75], use of PARPi to treat these tumors would represent a profound therapeutic advancement.